drugset / Trial / NCT04111172
A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma
RandomizedParallel-groupOpen-labelTreatment
Summary
This phase IIA trial investigates the side effects of Ad5.F35-hGCC-PADRE vaccine and to see how well it works in treating patients with gastrointestinal adenocarcinoma. Ad5.F35-hGCC-PADRE vaccine may help to train the patient's own immune system to identify and kill tumor cells and prevent it from coming back.
Timeline
- Start
- 2020-11-10
- Primary completion
- 2026-03-01
- Completion
- 2027-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE | Vaccine | 1e+11 unknown | Intramuscular |
| Subject | Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE | Vaccine | 1e+12 unknown | Intramuscular |
| Subject | Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE | Vaccine | 5e+12 unknown | Intramuscular |